in vitro News and Research

RSS

Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Cepheid today announced the release of Xpert® Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices.

16 Jun 2014

Beckman Coulter Life Sciences launches Aquios CL Clinical Flow Cytometer* for laboratory use

Beckman Coulter Life Sciences is set to transform the use of flow cytometry in the routine clinical laboratory with its latest offering, the Aquios CL Clinical Flow Cytometer*. Fully automated, with a small footprint, the instrument is the first authentic ‘LOAD & GO’ cytometry system.

13 Jun 2014

Study examines effect of phthalate exposure in humans’ sperm epigenetics

A new three-year, $440,000 study led by environmental health scientist Richard Pilsner at the University of Massachusetts Amherst is now underway to investigate whether phthalate levels in expectant fathers have an effect on the couples' reproductive success, via epigenetic modifications of sperm DNA.

12 Jun 2014

AtomoRapid blood test device named Best in Show at 2014 MDEA program

Atomo Diagnostics' multi-award winning AtomoRapid™ HIV last night was awarded Best in Show, and the winner of the In Vitro Diagnostics Category, at the 17th Medical Design Excellence Awards (MDEA), held in New York.

12 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Auxogyn receives clearance from FDA for Eeva System

Auxogyn, Inc. a leader in women's reproductive health, today announced that its first product, the Eeva System, received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Scientists develop new molecule for monitoring drug concentration

Monitoring the drug concentration in patients is critical for effective treatment, especially in cases of cancer, heart disease, epilepsy and immunosuppression after organ transplants.

9 Jun 2014

SurModics launches BioFX Liquid Nova-Stop Solution for TMB microwell substrates

SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. and a market leader for in vitro diagnostic assay components, today announced the launch of BioFX® Liquid Nova-Stop Solution, a non-corrosive, non-hazardous stop solution for TMB microwell substrates.

6 Jun 2014

Chinese FDA approves Waters ACQUITY UPLC TQD system as a medical device

Waters Corporation today announced that the Chinese Food and Drug Administration (CFDA) approved the registration of the ACQUITY UPLC TQD system for legal promotion and sale in China as a medical device for routine diagnostic applications and neonatal metabolites diseases screening.

5 Jun 2014

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

The Epstein-Barr virus (EBV) is a member of the herpes family that targets lymphocytes and epithelial cells. While the infection is usually benign, it can in some cases lead to acute infectious mononucleosis and can impair the immune system. EBV is also linked to several malignancies. There is currently no cure for removing EBV infections and very little success treating acute EBV infection and mononucleosis with drugs.

4 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

New discovery may shed light on how common cold triggers asthma attacks

Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold.

3 Jun 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Agena Bioscience acquires Sequenom’s Bioscience business

Agena Bioscience, Inc., a portfolio company of Telegraph Hill Partners (THP), today acquired the Bioscience business of Sequenom, Inc., which sells the MassARRAY® System for mass spectrometry-based detection of nucleic acids in research and clinical laboratories.

31 May 2014

in vitro News and Research

Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Beckman Coulter Life Sciences launches Aquios CL Clinical Flow Cytometer* for laboratory use

Study examines effect of phthalate exposure in humans’ sperm epigenetics

AtomoRapid blood test device named Best in Show at 2014 MDEA program

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Auxogyn receives clearance from FDA for Eeva System

Celsion signs definitive asset purchase agreement to acquire EGEN

Scientists develop new molecule for monitoring drug concentration

SurModics launches BioFX Liquid Nova-Stop Solution for TMB microwell substrates

Chinese FDA approves Waters ACQUITY UPLC TQD system as a medical device

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

New discovery may shed light on how common cold triggers asthma attacks

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Agena Bioscience acquires Sequenom’s Bioscience business

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

New approach could lead to more effective HIV vaccine

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

Vitamin D deficiency predicts prostate biopsy outcomes

Immucor's PreciseType HEA test receives FDA approval to predict blood compatibility

eBook: Using iPSCs models for human disease research and drug discovery eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News